Boehringer Ingelheim
For Healthcare Professionals
x

Registration Form

Information you provide when registering will be shared with the account owner and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC

25/07/2022  |  Author: Boehringer Ingelheim

Document ID: PC-MY-102569

Sequencing

Sequential treatment afatinib
RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - Data from GIOTAG and RESET studies
SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies)
Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC (CNS cohort)
GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort
MYSEREAL||GIOTRIF® followed by 3rd generation TKI in RESET study
SEREAL||Japan real world evidence supports sequential treatment with the use of upfront 2nd generation TKI
SEREAL||GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib
SEREAL||Post-hoc analyses from LUX-Lung trials: GIOTRIF(R) followed by 3rd generation TKI
SEREAL||Uptake of subsequent therapy in LUX-Lung 3, 6 and 7
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study
Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC

RELATED CONTENT